About the Company
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NBIX News
Neurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDD
Neurocrine Biosciences, Inc. (NBIX) announced positive results on Tuesday from its Phase 2 SAVITRI trial, which evaluated the ...
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital ...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the ...
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
SAN DIEGO, April 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the ...
Neurocrine Biosciences Inc NBIX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Where Neurocrine Biosciences Stands With Analysts
Stay informed and make well-considered decisions with our Ratings Table. Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous ...
Neurocrine Biosciences Stock (NASDAQ:NBIX), Analyst Ratings, Price Targets, Predictions
$138.09-7.31% RBC Capital ...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program ...
Neurocrine Biosciences, Inc. (NBIX) Stock: What the Analysts are Saying
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has a price-to-earnings ratio that is above its average at 55.94x. The stock has a 36-month beta value of 0.28. Opinions on the stock are mixed, with 8 ...
Neurocrine's Phase 2 SAVITRI Study Meets Primary Endpoint For NBI-1065845 In Adults With MDD
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced positive results on Tuesday from its Phase 2 SAVITRI trial, which evaluated the effectiveness and safety of NBI-1065845 in adult patients ...
Loading the latest forecasts...